Cargando…
Antisense Oligonucleotide Therapy: From Design to the Huntington Disease Clinic
Huntington disease (HD) is a fatal progressive neurodegenerative disorder caused by an inherited mutation in the huntingtin (HTT) gene, which encodes mutant HTT protein. Though HD remains incurable, various preclinical studies have reported a favorable response to HTT suppression, emphasizing HTT lo...
Autores principales: | Rook, Morgan E., Southwell, Amber L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8899000/ https://www.ncbi.nlm.nih.gov/pubmed/35254632 http://dx.doi.org/10.1007/s40259-022-00519-9 |
Ejemplares similares
-
Hydrocephalus Complicating Intrathecal Antisense Oligonucleotide Therapy for Huntington's Disease
por: Stoker, Thomas B., et al.
Publicado: (2020) -
Allele-Specific Suppression of Mutant Huntingtin Using Antisense Oligonucleotides: Providing a Therapeutic Option for All Huntington Disease Patients
por: Skotte, Niels H., et al.
Publicado: (2014) -
Biological Aging and the Cellular Pathogenesis of Huntington’s Disease
por: Machiela, Emily, et al.
Publicado: (2020) -
Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease
por: Sardone, Valentina, et al.
Publicado: (2017) -
Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS
por: Østergaard, Michael E., et al.
Publicado: (2013)